This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Nuvaira Inc. (formerly Holaira; medical devices to treat obstructive lung diseases) raised $79mm in its Series E financing led by US Venture Partners, which was joined by other new backers Endeavour Vision, Qiming Venture Partners, Lightstone Ventures, and Richard King Mellon Foundation and returning shareholders Advanced Technology Ventures, Morgenthaler Ventures, Split Rock Partners, Versant Ventures, Vertex Venture Holdings, and Windham Venture Partners. The company will use the funds for the pivotal AIRFLOW-3 clinical trial of its lung denervation system required to gain FDA approval, and to create a clinical development strategy in key markets in Europe.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?